Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Key facts

Sponsor

Dutch Childhood Oncology Group

Principal Investigator

Rob Pieters, MD, MSC, PhD

Prinses Maxima Centrum voor kinderoncologie Utrecht

Intervention

anti-thymocyte globulin(biological)

Enrollment

445 enrolled

Eligibility

1 years · All sexes

Timeline

2006

Study locations (13)

• Children's Hospital Boston, Boston, Massachusetts, United States
• St. Jude Children's Research Hospital, Memphis, Tennessee, United States
• M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
• Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
• St. Anna Children's Hospital, Vienna, Austria
• Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium
• University Hospital Motol, Prague, Czechia
• CHR Hotel Dieu, Nantes, France
• University Medical Center Hamburg - Eppendorf, Hamburg, Germany
• Medizinische Hochschule Hannover, Hanover, Germany
• Nuovo Ospedale San Gerardo at University of Milano-Bicocca, Monza, Italy
• Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
• Great Ormond Street Hospital for Children, London, England, United Kingdom

Collaborators

BFM Germany · CORS Monza Italy · Associazione Italiana Ematologia Oncologia Pediatrica · Australian and New Zealand Children's Oncology Group · BFM Austria · CLCG France Belgium Portugal · COALL Germany · CPH, Czech republic · DFCI consortium USA · FRALLE France · Hong Kong Government · MD Anderson USA · NOPHO Scandinavian countries · PINDA, Chile · PPLLSG Poland · Seattle USA · SJCRH USA · UKCCSG United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute biphenotypic leukemia

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07517510
  HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
  Guangdong Second Provincial General Hospital
• RECRUITINGPHASE1, PHASE2NCT07356154
  A Study of Revumenib and Mezigdomide in People With Leukemia
  Memorial Sloan Kettering Cancer Center
• RECRUITINGNCT07537738
  Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
  Peking University People's Hospital
• RECRUITINGPHASE1, PHASE2NCT05589896
  A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
  Ossium Health, Inc.
• RECRUITINGNANCT05794880
  MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
  Medical College of Wisconsin
• ACTIVE NOT RECRUITINGPHASE2NCT03399773
  Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
  Fred Hutchinson Cancer Center
• RECRUITINGPHASE1, PHASE2NCT04797767
  Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
  University of Washington
• ACTIVE NOT RECRUITINGPHASE2NCT04975919
  Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
  M.D. Anderson Cancer Center

See all trials for Acute biphenotypic leukemia →